The single question I get most often in the consultation room right now is some version of: "Should I be on the compounded version or the real thing?" The answer changed in late 2025 when the FDA officially removed semaglutide and tirzepatide from the drug shortage list, and most of the patients I see have not yet absorbed what that change actually means for their treatment. So this is the article I wish I could hand every patient before they sit down — what the FDA update did, what compounding pharmacies are now permitted to do, and how I think about brand versus compounded GLP-1 when I am writing a prescription for a real person with a real budget.
I am going to be direct with you: this is not a binary good-versus-bad conversation. Both pathways have legitimate clinical roles. The question is which one fits your specific situation, and that requires more nuance than the social media version of this debate allows for.
What the FDA actually changed
For roughly two and a half years, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) sat on the FDA shortage list. Under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, that designation gave compounding pharmacies legal cover to produce versions of those molecules to fill the supply gap. That is how the compounded GLP-1 market exploded — telehealth platforms, med spas, and weight loss clinics across the country began offering compounded semaglutide and tirzepatide at a fraction of the brand cost.
In October 2024, the FDA declared the tirzepatide shortage resolved. In February 2025, semaglutide followed. Once a drug is off the shortage list, the legal basis for routine large-scale compounding of that molecule disappears. 503B outsourcing facilities had to wind down production within 60 days; 503A pharmacies got slightly longer. The grace periods are now expired.
What that does not mean: compounded semaglutide is illegal across the board. A 503A pharmacy can still compound a customized formulation for a specific patient if there is a documented clinical reason the commercial product will not work — typically a different dose, a different route, or the addition of B12 or another adjunct. What it does mean: the days of identical-to-brand compounded semaglutide being sold at scale through telehealth platforms are functionally over. If you are still receiving that, your clinician should be able to explain the specific clinical justification on your chart, and you should ask to see it.
How I think about brand versus compounded clinically
I trained in emergency medicine, cardiac ICU, and the cath lab before I moved into outpatient hormone and metabolic work. Seventeen years of watching what happens when medication supply chains break down made me a stickler about source. When I write a prescription, I want to know what is in the vial, where it came from, and who is accountable if something goes wrong.
Brand-name semaglutide and tirzepatide are FDA-approved, manufactured under cGMP in inspected facilities, with a defined potency, a defined excipient profile, and a complete adverse event reporting infrastructure behind them. When I prescribe Wegovy or Zepbound, I know precisely what the patient is injecting.
Compounded GLP-1 is more variable. A high-quality 503B facility producing a properly customized formulation under clinical justification can be perfectly safe. A questionable online operation drop-shipping unregulated peptide from a non-pharmacy source is something else entirely — and the patient often cannot tell the difference from the product label. I have seen patients arrive at the Columbus clinic with vials they bought from "research peptide" sites, and that is not what we are talking about when we discuss legitimate compounded therapy. That is unregulated black-market product, and it has no place in a clinical medical weight loss program.
The honest middle ground: there are legitimate clinical reasons a compounded formulation may still be appropriate post-shortage — for example, a patient who needs a non-standard dose to titrate through a tolerance issue, or a patient whose response curve calls for a customized B12-paired preparation. Those decisions are made on the chart, not by a telehealth algorithm.
The mechanism — why this drug works the way it does
Semaglutide and tirzepatide are GLP-1 receptor agonists (tirzepatide is a dual GLP-1/GIP agonist, which is part of why it tends to outperform). They mimic an endogenous incretin hormone the small intestine releases in response to a meal. Three things happen at the receptor: gastric emptying slows, so you feel full longer on less food; central appetite signaling at the hypothalamus shifts, so the food noise quiets down; and pancreatic insulin secretion improves in response to glucose, which corrects some of the insulin resistance that is usually driving mid-life weight gain in the first place.
That third mechanism is the one most patients underappreciate. A meaningful percentage of the patients I evaluate for weight loss have fasting insulin in the high teens or twenties with HbA1c that is technically still under 5.7. That is metabolic dysfunction the standard primary care panel never flagged, and it is the engine behind the weight gain. GLP-1 therapy, properly dosed, addresses that engine — not just appetite.
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
The reason this matters for the brand-versus-compounded conversation: the molecule has to be the actual molecule, dosed accurately, for the receptor pharmacology to work. A compounded preparation that is sub-potent will produce blunted weight loss and minor appetite suppression, and the patient will conclude that "GLP-1 did not work for me" when in fact they were not on a therapeutic dose.
What I look for when deciding which to prescribe
When I sit down with a patient at the first weight loss consultation, the brand-versus-compounded question is downstream of several other questions. In order:
Is the patient actually a GLP-1 candidate? A complete metabolic and hormonal panel is non-negotiable before I prescribe. Insulin, HbA1c, lipid panel, full thyroid (TSH, free T3, free T4, reverse T3, antibodies), full sex hormones, and cortisol pattern. If the patient's weight gain is being driven by untreated hypothyroidism or hormone decline, GLP-1 is not the first move — addressing the actual driver is. Hormone optimization frequently precedes or accompanies GLP-1 in the women I see, and men's testosterone replacement is often the missing piece for the male patients.
Are there contraindications? Personal or family history of medullary thyroid carcinoma. MEN2. Prior pancreatitis. Active gallbladder disease. Severe gastroparesis. These are absolute or near-absolute contraindications and they apply equally to brand and compounded.
What is the patient's coverage situation? If commercial insurance covers Wegovy or Zepbound for the patient's BMI and comorbidity profile, that is almost always the cleanest path. The supply is reliable, the pen is convenient, the dosing is standardized, and the cost is manageable. If the patient is fully cash-pay and the brand is genuinely out of reach, the conversation shifts — and that is where a legitimate, individualized compounded preparation may have a clinical role, with the appropriate documentation and pharmacy partnership.
What is the long-term framework? If the plan is to use GLP-1 as a defined-window intervention with a structured taper into a maintenance phase, that changes how I think about source and titration. If the plan is indefinite maintenance dosing, supply reliability becomes a bigger consideration.
How the program runs in practice
The 90-day structured phase exists because that is the timeframe in which I can actually evaluate whether the intervention is working. We do not just write the prescription and disappear. The first 30 days are the conservative starting dose — typically 0.25 mg semaglutide or 2.5 mg tirzepatide weekly — with a written GI side effect protocol the patient takes home. Days 30 through 60 are titration based on tolerance and response, paired with nutritional counseling focused specifically on protein intake (1.6 to 2.2 g per kg of lean body mass) and resistance training, because GLP-1-induced weight loss without adequate protein and load-bearing exercise costs disproportionate lean mass.
At day 90 we re-run labs. Insulin, HbA1c, lipid panel, and a body composition reassessment. If the data shows fat mass coming down and lean mass holding, we are on the right track and the plan continues. If lean mass is dropping faster than I would like, the protein and training prescription gets sharper before the next titration. The weight loss assessment at the start gives us the baseline we are measuring against.
The Warner Robins and middle Georgia patient population I see — including the active-duty and retired military folks coming in from Robins Air Force Base — tends to do well on this framework because they are accustomed to structured protocols and follow-through. The patients who struggle are typically the ones who skipped the workup, started GLP-1 from a telehealth source without baseline labs, and arrive in my office six months in asking why the scale stopped moving and why they feel exhausted. The answer is almost always sitting in labs we have not yet run.
What this means for your decision
If you are currently on a compounded GLP-1 from a telehealth platform and the source is not crystal clear post-shortage, the right next step is to get into a clinic that will pull baseline labs, document candidacy, and either transition you to brand product or to a properly justified individualized compounded preparation through a verified pharmacy partner. If you are weighing starting therapy, do the workup before you pick a source — the workup tells us whether GLP-1 is even the right tool, and if it is, which formulation and dose makes sense for your physiology and your budget.
Bring whatever labs you have, whatever prior weight loss history you have, and a list of any medications and supplements you are currently taking. We will spend the first visit on the clinical picture and the second visit on the data, and the prescription decision — brand or appropriately compounded, semaglutide or tirzepatide, dose and titration schedule — will be grounded in what your body is actually doing rather than what an internet algorithm suggested. Use the online booking portal for the Columbus clinic or the Warner Robins clinic, or call either location directly. Bring the questions; we will work through them together.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.